Anonymousabout 4 hours ago
A new generation of cancer immunotherapies — including bispecific antibodies, tumor-infiltrating lymphocyte (TIL) therapy, and next-generation CAR-T cells — is producing striking tumor response rates in clinical trials, particularly in blood cancers and select solid tumors. But the treatments carry costs exceeding $500,000 per patient, face steep manufacturing bottlenecks, and emerge from early-phase trials where historically only 5% of oncology drugs survive to FDA approval — raising hard questions about access, scalability, and whether media enthusiasm risks distorting patient expectations.